TME Pharma: Invest Securities reduces its target

(CercleFinance.com) - Invest Securities confirms its Buy rating on TME Pharma shares, with a price target reduced from 0.
61 to 0.49 euros.

On Monday after trading, the company announced the launch of a secured AK via a guarantee agreement underwritten by professional investors who contributed €2.2 million. A total of €2.35m was raised, extending the company's financial visibility to the end of 2024, or even the beginning of 2025.

The company intends to prioritize (i) the development of its GBM program and (ii) the plan to identify industrial and/or financial partners to support the upcoming Ph II trial in GBM.

Finally, TME Pharma plans to sell the rights to its NOX-E36 product to generate revenues, the analyst reports.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.